These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34593018)

  • 1. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
    Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
    Jain MR; Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Ranvir R; Kadam S; Patel H; Swain P; Roy SS; Das N; Karmakar E; Wahli W; Patel PR
    Liver Int; 2018 Jun; 38(6):1084-1094. PubMed ID: 29164820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
    Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
    Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
    Abd El-Haleim EA; Bahgat AK; Saleh S
    Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
    Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis.
    Hassan NF; Nada SA; Hassan A; El-Ansary MR; Al-Shorbagy MY; Abdelsalam RM
    Inflammation; 2019 Jun; 42(3):1056-1070. PubMed ID: 30737662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual PPAR-α/γ agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin.
    Makled MN; Sharawy MH; El-Awady MS
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1569-1576. PubMed ID: 31367862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
    Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD.
    Ezhilarasan D
    Metabolism; 2024 Jun; 155():155912. PubMed ID: 38609038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saroglitazar attenuates renal fibrosis induced by unilateral ureteral obstruction via inhibiting TGF-β/Smad signaling pathway.
    Makled MN; El-Kashef DH
    Life Sci; 2020 Jul; 253():117729. PubMed ID: 32348836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids.
    Sarkar S; Kumari D; Gupta SK; Sharma V; Mukhi S; Kamboj P; Sasibhushan V; Rai RK; Jatavallabhula SL; Mahajan D; Kumar Y; Kumar A; Dikshit M
    Biomed Pharmacother; 2021 Dec; 144():112357. PubMed ID: 34794234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression.
    Abd El-Haleim EA; Bahgat AK; Saleh S
    World J Gastroenterol; 2016 Mar; 22(10):2931-48. PubMed ID: 26973390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Bandyopadhyay S; Samajdar SS; Das S
    Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102174. PubMed ID: 37380128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
    Joshi SR
    Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
    Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
    Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
    Goyal O; Nohria S; Goyal P; Kaur J; Sharma S; Sood A; Chhina RS
    Sci Rep; 2020 Dec; 10(1):21117. PubMed ID: 33273703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
    Susutlertpanya W; Wakuda H; Otani N; Kuramoto T; Li L; Kuranari M; Sekiguchi A; Kudo H; Uchida T; Imai H; Uemura N
    Life Sci; 2019 Jul; 228():251-257. PubMed ID: 31078545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.